China’s biotech sector reported a record 5,215 clinical drug trials in 2025, according to a SCMP analysis of National Medical Products Administration (NMPA) data published June 24. The figure represents a 23% increase over 2024’s 4,240 registered trials and cements China’s position as the world’s second-largest clinical trial market by volume, behind only the United States.
Cancer treatments remain the dominant research focus, accounting for 42% of all trials, followed by metabolic disorders (15%) and infectious diseases (11%). The surge underscores Beijing’s push to make biotechnology a strategic pillar industry — a designation that comes with R&D subsidies, accelerated approval pathways, and talent recruitment incentives.
Why It Matters
The clinical trial boom has direct implications for foreign pharmaceutical and biotech companies evaluating China as a clinical development market. Three trends stand out:
First, China is no longer just a manufacturing base for Western pharma. Of the 5,215 trials registered in 2025, 68% were initiated by domestic Chinese biotech firms. This is up from 51% in 2021. Chinese companies are increasingly developing first-in-class molecules, not just biosimilars and generics. In 2025, Chinese biotech firms signed 47 outbound licensing deals with global pharmaceutical companies, according to DealForma data cited by SCMP — a 35% increase from 2024.
Second, regulatory acceleration is real. The NMPA’s Center for Drug Evaluation (CDE) shortened average clinical trial approval times from 18 months in 2020 to 5.8 months in 2025 for innovative drugs. Priority review pathways for breakthrough therapies now average 3.2 months. This makes China one of the fastest major markets for trial initiation globally.
Third, talent depth is improving. China has produced 12,000 PhD-level life sciences graduates annually since 2023, per Goldman Sachs, creating a deep bench for domestic R&D. The same report flagged pharmaceutical and biotech as the sectors most likely to benefit from China’s demographic transition, as an aging population — 22% of Chinese are now 60 or older — drives demand for oncology, cardiovascular, and neurodegenerative disease treatments.
The Numbers Behind the Boom
- 5,215 clinical drug trials registered with the NMPA in 2025 — a record high, up 23% from 4,240 in 2024
- 42% of trials focused on oncology, followed by metabolic disease (15%) and infectious disease (11%)
- 68% of trials initiated by domestic Chinese firms, up from 51% in 2021
- 47 outbound licensing deals signed by Chinese biotech firms in 2025, up 35% year-over-year
- 5.8 months average CDE approval time for innovative drug trials, down from 18 months in 2020
- 12,000 PhD-level life sciences graduates per year since 2023
- 22% of China’s population now aged 60 or older, driving structural demand for advanced therapeutics
The Flip Side: Challenges Remain
For all the momentum, the biotech sector faces headwinds that foreign companies should factor into their China strategy. Venture capital funding for early-stage Chinese biotechs dropped 18% in 2025 compared to 2024, according to SCMP, as global investors grew more cautious about China exposure. IPO windows in Hong Kong and the US remain narrow — only 8 Chinese biotech firms went public in 2025, down from 22 in 2021. Several private firms are now pivoting to licensing deals and strategic partnerships as alternatives to IPO exits.
Regulatory risk is also rising. The new audit liability rules (see our policy signals briefing) could slow the pace of Big Four involvement in biotech financial reporting. And a growing focus on data security is adding compliance overhead for trial sponsors that need to transfer patient data across borders — a friction point not going away.
Where the Opportunities Are
For foreign investors and pharmaceutical companies, the most actionable entry points in China’s biotech market are:
- Out-licensing from Chinese biotechs: With IPO exits constrained, Chinese firms are more willing to negotiate global rights deals. Expected deal values are 20–30% lower than 2021 levels, creating a buyer’s market.
- CRO and CDMO services: China’s clinical trial infrastructure — 1,800+ GCP-certified hospitals — makes it a cost-effective site for global trials. Phase I trial costs in China are roughly 60% of US levels.
- Cell and gene therapy: Chinese firms now account for 30% of global CAR-T clinical trials, the highest share of any country. Regulatory pathways for cell therapies are relatively mature compared to other emerging modalities.
One Data Point
68% — the share of China’s 2025 clinical trials initiated by domestic firms, up from 51% in 2021. For foreign pharma, the implications are twofold: more potential licensing partners, but also a more competitive landscape for patient recruitment — particularly in oncology, where the trial density per patient has doubled since 2022.
— China Gateway 360 —
Remote China market entry support, built around execution.